Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Daiichi Sankyo
Healthtrust
Baxter
UBS
Julphar
Citi
Merck
Johnson and Johnson

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,217,713

« Back to Dashboard

Which drugs does patent 7,217,713 protect, and when does it expire?

Patent 7,217,713 protects ISENTRESS, DUTREBIS, and ISENTRESS HD, and is included in four NDAs.

Protection for ISENTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-two patent family members in thirty-two countries.
Summary for Patent: 7,217,713
Title:N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Abstract:N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: ##STR00001## are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds-are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.
Inventor(s): Crescenzi; Benedetta (Rome, IT), Gardelli; Cristina (Ariccia, IT), Muraglia; Ester (Rome, IT), Nizi; Emanuela (Siena, IT), Orvieto; Federica (Rome, IT), Pace; Paola (Rome, IT), Pescatore; Giovanna (Cosenza, IT), Petrocchi; Alessia (Rome, IT), Poma; Marco (Grosseto, IT), Rowley; Michael (Axa, IT), Scarpelli; Rita (Rome, IT), Summa; Vincenzo (Velletri, IT)
Assignee: Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.A. (Pomezia (Rome), IT)
Application Number:11/491,815
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,217,713

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck Sharp Dohme ISENTRESS raltegravir potassium POWDER;ORAL 205786-001 Dec 20, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme ISENTRESS raltegravir potassium TABLET, CHEWABLE;ORAL 203045-001 Dec 21, 2011 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme ISENTRESS raltegravir potassium TABLET, CHEWABLE;ORAL 203045-002 Dec 21, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme DUTREBIS lamivudine; raltegravir potassium TABLET;ORAL 206510-001 Feb 6, 2015 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme ISENTRESS raltegravir potassium TABLET;ORAL 022145-001 Oct 12, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck Sharp Dohme ISENTRESS HD raltegravir potassium TABLET;ORAL 022145-002 May 26, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,217,713

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,169,780 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase ➤ Subscribe
7,435,734 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase ➤ Subscribe
7,820,660 N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,217,713

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland 369223 ➤ Subscribe
New Zealand 533057 ➤ Subscribe
Norway 2008007 ➤ Subscribe
Norway 325206 ➤ Subscribe
Norway 20042165 ➤ Subscribe
Netherlands 300340 ➤ Subscribe
Mexico PA04003932 ➤ Subscribe
Luxembourg 91428 ➤ Subscribe
South Korea 100862879 ➤ Subscribe
South Korea 20040047981 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Accenture
Baxter
US Department of Justice
Farmers Insurance
Cerilliant
Daiichi Sankyo
Healthtrust
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot